Ittipat Meewan, Ph.D.

     My research focuses on the use of computational simulation, machine learning, bioinformatics, and data analytic approaches to design and optimize new medications for various diseases, including viral pathogens such as Hepatitis C virus (HCV), Zika virus (ZIKV), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Human papillomavirus (HPV), parasitic such as Entamoeba histolytica, and cancer. By screening specific biological targets, our lab aims to discover novel drugs and validate them experimentally. We also investigate biological systems for target identification and predict potential effects of drug candidates, as well as identifying new potential uses for existing drugs.

1.Meewan I, Kattoula J, Kattoula JY, Skinner D, Fajtová P, Giardini MA, et al. Discovery of Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L. Pharmaceuticals. 2022;15(6).

2.Meewan I, Zhang X, Roy S, Ballatore C, O’Donoghue AJ, Schooley RT, et al. Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant. ACS Omega. 2019 Oct 15;4(16):16999–7008.

3.Meewan I, Shiryaev SA, Huang CT, Lin YW, Chuang CH, Terskikh AV, et al. Allosteric inhibitors of Zika virus NS2B-NS3 protease targeting protease in super-open conformation. bioRxiv. 2022 Jan 1;2022.03.09.483711.